Skip to main content

Table 2 IV iron and ESA treatments

From: A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO)

 

Retrospective IS phase

Prospective IIM phases

 

0–3 months

0–3 months

3–6 months

6–9 months

9–12 months

IV iron treatment

n = 195

n = 195

n = 171

n = 156

n = 151

Number of IV iron doses per patient

     

Mean (SD)

5.4 (3.0)

5.6 (3.1)

5.1 (2.8)

5.0 (2.7)

5.2 (3.0)

p-valuea

 

0.4664

0.3533

0.2313

0.5874

Cumulative IV iron dose (mg) per patient

     

Mean (SD)

534.4 (296.7)

561.0 (305.8)

515.2 (283.1)

503.2 (267.2)

528.5 (301.2)

Mean (SD) monthly

178.1 (98.9)

187.0 (101.9)

171.7 (94.4)

167.7 (89.1)

176.2 (100.4)

p-valuea

 

0.3071

0.5650

0.3530

0.8036

ESA treatment

n = 195

n = 195

n = 171

n = 156

n = 151

Patients with ESA, n (%)

175 (89.7)

163 (83.6)

153 (89.5)

143 (91.7)

140 (92.7)

Number of ESA doses per patient

     

Mean (SD)

19.4 (11.1)

17.5 (11.7)

20.1 (12.3)

18.6 (11.3)

20.1 (12.5)

Median (IQR)b

14.0 (12.0–26.0)

14.0 (8.0–25.0)

17.0 (10.0–29.0)

15.0 (9.0–26.0)

16.0 (9.0–32.0)

p-valuea

 

0.0468

0.9228

0.2840

0.8250

Cumulative ESA dose (1000 IU) weekly per patient

     

Mean (SD)

8.0 (8.1)

7.4 (6.5)

8.7 (8.0)

9.0 (9.3)

8.9 (7.4)

Median (IQR)b

6.0 (3.3–10.7)

5.7 (2.7–10.0)

6.7 (2.9–12.0)

6.0 (3.0–10.8)

7.0 (3.0–11.0)

p-valuea

 

0.4131

0.5745

0.8107

0.3248

  1. aP-value obtained from Wilcoxon rank-sum test by comparison to the retrospective IS phase
  2. bData not normally distributed are presented as median values
  3. ESA erythropoiesis-stimulating agent, IIM iron isomaltoside, IQR interquartile range, IS iron sucrose, IU international unit, IV intravenous, n number of patients, SD standard deviation